[an error occurred while processing this directive]

Advanced Ultrasound in Diagnosis and Therapy ›› 2024, Vol. 8 ›› Issue (1): 22-28.doi: 10.37015/AUDT.2024.230044

• • 上一篇    下一篇

  

  • 收稿日期:2023-07-30 接受日期:2023-09-28 出版日期:2024-03-30 发布日期:2024-02-04

Identification of Differently Expressed miRNAs and Genes between Benign Prostatic Hyperplasia and Prostate Cancer

Yuqing Huang, MDa, Cui Lei, BSb(), Xinyu Zhao, PhDc, Jing Xiao, PhDd, Xian-Quan Shi, PhDa,*   

  1. aDepartment of Ultrasound, Beijing Friendbship Hospital, Capital Medical University, Beijing, China
    bDepartment of Gynaecology and Obstetrics, Chang An Hospital, Xian, China
    cClinical Epidemiology & EBM Unit, Beijing Friendship Hospital, Capital Medical University
    dDepartment of Urinary Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • Received:2023-07-30 Accepted:2023-09-28 Online:2024-03-30 Published:2024-02-04
  • Contact: Department of Ultrasound, Beijing Friendbship Hospital, Capital Medical University, 95 Yong An Road, Beijing, China.e-mail: sonoshixq@ccmu.edu.cn

RichHTML

6

PDF (PC)

364

Abstract:

Objective MicroRNAs (miRNAs) play important roles in various diseases’ development and progression. The aim of this study is to identify the differently expressed miRNAs (DEmiRNAs) and differently expressed genes (DEGs) between BPH and PCa.

Methods Selecting BPH and PCa tissues from GEO database (GSE118038 as test dataset; GSE30994 as validation dataset), we identified DEmiRNAs and DEGs between BPH and PCa using GEO2R online tool and “Deseq2” R package. We applied random forest method to select hub DEmiRNAs, combining age and BMI, to establish a nomogram model for BPH detection. Finally, GO and KEGG enrichment analyses were conducted to explore the underlying mechanisms and pathways of DEmiRNAs in BPH.

Results We found 26 DEmiRNAs between BPH and PCa, of which 21 DEmiRNAs were up-regulated and 5 DEmiRNAs were down-regulated. Via forest random method, we selected miR-636, miR-324-3p, miR-210-3p and miR-3615 as hub DEmiRNAs in BPH. Combing these four hub DEmiRNAs, age and BMI, we established a nomogram model to distinguish BPH from PCa. Through “miRWalk” online tool, we targeted 499 hub DEGs between BPH and PCa, and found most of genes enriched in muscle system process, muscle contraction, contractile fiber, myofibril, actin binding, passive transmembrane transporter activity, focal adhesion, axon guidance.

Conclusion Our results suggested that miR-636, miR-324-3p, miR-210-3p and miR-3615 might the hub DEmiRNAs between BPH and PCa, which may play a crucial role to distinguish BPH from PCa.

Key words: Benign prostate hyperplasia, miRNA, Prostate cancer, Nomogram, BMI

"

"

DEmiRNAs baseMean log2FC lfcSE stat p-value Padj
hsa-miR-7706 43.74332 2.646137 0.413391 6.401056 1.54E-10 2.96E-08
hsa-miR-210-3p 206.0853 2.554497 0.410772 6.218768 5.01E-10 4.89E-08
hsa-miR-324-3p 40.06085 2.457721 0.436168 5.634801 1.75E-08 1.14E-06
hsa-miR-1180-3p 46.64679 2.154102 0.42419 5.078148 3.81E-07 1.31E-05
hsa-miR-296-5p 5.398728 2.470078 0.493403 5.00621 5.55E-07 1.62E-05
hsa-miR-3615 301.8162 2.135752 0.430592 4.960039 7.05E-07 1.79E-05
hsa-miR-1306-3p 5.838892 2.009393 0.409355 4.908687 9.17E-07 2.23E-05
hsa-miR-636 10.91144 2.739224 0.581551 4.710204 2.47E-06 5.04E-05
hsa-miR-339-3p 115.3661 2.049528 0.437868 4.680703 2.86E-06 5.40E-05
hsa-miR-3200-3p 3.870076 2.358303 0.516304 4.567666 4.93E-06 8.49E-05

"

"

"

"

"

"

"

[1] Kim EH, JA Larson, and GL Andriole. Management of benign prostatic hyperplasia. Annu Rev Med 2016; 67:137-151.
doi: 10.1146/annurev-med-063014-123902 pmid: 26331999
[2] Zhu C, DQ Wang, H Zi, Q Huang, JM Gu, LY Li, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res 2021; 8:64.
doi: 10.1186/s40779-021-00359-8 pmid: 34879880
[3] Chen J, D Zhang, W Yan, D Yang, and B Shen. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era . Biomed Res Int 2013;901578.
[4] Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20 Suppl 3:S11-18.
[5] McNeal JE, EA Redwine, FS Freiha, and TA Stamey. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
doi: 10.1097/00000478-198812000-00001 pmid: 3202246
[6] Institute, NC. Understanding prostate changes: a health guide for men. https://www.cancer.gov/types/prostate/understanding-prostate-changes.
[7] Sommers SC. Endocrine changes with prostatic carcinoma. Cancer 1957; 10:345-358.
pmid: 13426991
[8] Bostwick DG, WH Cooner, L Denis, GW Jones, PT Scardino, and GP Murphy, The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70:291-301.
doi: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4 pmid: 1376199
[9] Tanaka T, T Koie, C Ohyama, Y Hashimoto, A Imai, Y Tobisawa, et al. Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy. Jpn J Clin Oncol 2017; 47:1078-1082.
doi: 10.1093/jjco/hyx119 pmid: 28973396
[10] JY Joung, SO Yang, HK Seo, TS Kim, KS Han, J.Chung, et al. Incidental prostate cancer detected by cystoprostatectomy in Korean men. Urology 2009; 73:153-157.
doi: 10.1016/j.urology.2008.02.040 pmid: 18407328
[11] He B, Z Zhao, Q Cai, Y Zhang, P Zhang, S Shi, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 2020; 16:2628-2647.
doi: 10.7150/ijbs.47203 pmid: 32792861
[12] Greco F, A Inferrera, R La Rocca, M Navarra, M Casciaro, G Grosso, et al. The potential role of microRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 2019; 5:497-507.
doi: S2405-4569(18)30009-9 pmid: 29398458
[13] Macedo Hair G, F Fonseca Nobre, and P Brasil. Characterization of clinical patterns of dengue patients using an unsupervised machine learning approach. BMC Infect Dis 2019; 19:649.
doi: 10.1186/s12879-019-4282-y pmid: 31331271
[14] Yan J, L Liu, W Wang, Y Zhao, KK Li, K Li, et al. Radiomic features from multi-parameter MRI combined with clinical parameters predict molecular subgroups in patients with medulloblastoma. Front Oncol 2020; 10:558162.
doi: 10.3389/fonc.2020.558162
[15] De Nunzio C, S Ahyai, R Autorino, A Bachmann, W Bialek, A Briganti, et al. Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities. Eur Urol 2011; 60:1205-1206.
doi: 10.1016/j.eururo.2011.08.055 pmid: 21930341
[16] Langan RC, Benign prostatic hyperplasia. Prim Care 2019; 46:223-232.
doi: S0095-4543(19)30006-5 pmid: 31030823
[17] Wang S, Q Mao, Y Lin, J Wu, X Wang, X Zheng, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis 2012; 15:265-272.
doi: 10.1038/pcan.2011.65
[18] Wang YB, L Yang, YQ Deng, SY Yan, LS Luo, P Chen, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med 2022; 20:495.
doi: 10.1186/s12967-022-03722-y
[19] Li BH, T Deng, Q Huang, H Zi, H Weng, and XT Zeng. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. Am J Mens Health 2019; 13:1557988319870382.
[20] Parsons JK, AV Sarma, K McVary, and JT Wei. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009; 182:S27-S31.
[21] Kabekkodu SP, V Shukla, VK Varghese, DS J, S Chakrabarty, and K Satyamoorthy. Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc 2018; 93:1955-1986.
doi: 10.1111/brv.12428 pmid: 29797774
[22] Zhang N, Z Li, F Bai, N Ji, Y Zheng, Y Li, et al. MicroRNA expression profiles in benign prostatic hyperplasia. Mol Med Rep 2018; 17:3853-3858.
doi: 10.3892/mmr.2017.8318 pmid: 29359788
[23] Cochetti G, G Poli, G Guelfi, A Boni, MG Egidi, and E Mearini. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther 2016; 9:7545-7553.
doi: 10.2147/OTT
No related articles found!
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
[an error occurred while processing this directive]